Second-generation TKIs such as dacomitinib or afatinib that covalently bind to EGFR have been developed, and afatinib has recently obtained marketing approval for first-line treatment of lung cancer patients with common activating EGFR mutations [11]. This evidence concerns the gene EGFR and lung carcinoma.